ConductScience.org, home

Paper39007347

FLT3/CD99 Bispecific Antibody-Based Nanoparticles for Acute Myeloid Leukemia.

Ali A and 8 others. Cancer Res Commun, 2024. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. FLT3/CD99 Bispecific Antibody-Based Nanoparticles for Acute Myeloid Leukemia. Papers, record 39007347. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39007347

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
FLT3/CD99 Bispecific Antibody-Based Nanoparticles for Acute Myeloid Leukemia.
PubMed
Journal
Cancer Res Commun
PubMed
Year
2024
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
3
iCite
Relative citation ratio, by iCite
0.55, provisional
iCite
Revised in PubMed
2025-03-30
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
fms-Like Tyrosine Kinase 3Major topic
Leukemia, Myeloid, AcuteMajor topic
Antibodies, BispecificMajor topic
NanoparticlesMajor topic
12E7 AntigenMajor topic
Animals
Humans
Mice
Cell Line, Tumor
Xenograft Model Antitumor Assays
Female

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA014089NCI NIH HHSUnited StatesP30CA014089PubMed and NIHNIH RePORTER
R01 CA248381NCI NIH HHSUnited StatesR01CA248381PubMed and NIHNIH RePORTER

Download CSV of grants

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130651634Targeting FLT3 mutations in AML: review of current knowledge and evidence.Leukemia2019https://conductscience.org/library/papers/30651634PubMed
235422094CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML.Leukemia2022https://conductscience.org/library/papers/35422094PubMed
31695726Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor.Oncogene1990https://conductscience.org/library/papers/1695726PubMed
422488197Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients.J Surg Oncol2012https://conductscience.org/library/papers/22488197PubMed
511535508
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.
Blood2001https://conductscience.org/library/papers/11535508PubMed
62479542The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product.EMBO J1989https://conductscience.org/library/papers/2479542PubMed
710709783CD99 monoclonal antibody induce homotypic adhesion of Jurkat cells through protein tyrosine kinase and protein kinase C-dependent pathway.Immunol Lett2000https://conductscience.org/library/papers/10709783PubMed
831371417Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemia.Haematologica2020https://conductscience.org/library/papers/31371417PubMed
922147690Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains.J Biol Chem2012https://conductscience.org/library/papers/22147690PubMed
1026578439Elastin-like polypeptides: Therapeutic applications for an emerging class of nanomedicines.J Control Release2016https://conductscience.org/library/papers/26578439PubMed
1114961034CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease.Leukemia2004https://conductscience.org/library/papers/14961034PubMed
1235680852Resistance to targeted therapies: delving into FLT3 and IDH.Blood Cancer J2022https://conductscience.org/library/papers/35680852PubMed
1337116523
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet2023https://conductscience.org/library/papers/37116523PubMed
1421109889Characterizing the size, shape, and compactness of a polydisperse prolate ellipsoidal particle via quadruple-detector hydrodynamic chromatography.Analyst2011https://conductscience.org/library/papers/21109889PubMed
1533818756De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017.Cancer2021https://conductscience.org/library/papers/33818756PubMed
1632916604Adaptable antibody Nanoworms designed for non-Hodgkin lymphoma.Biomaterials2020https://conductscience.org/library/papers/32916604PubMed
1711090077Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.Blood2000https://conductscience.org/library/papers/11090077PubMed
1831665578Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.N Engl J Med2019https://conductscience.org/library/papers/31665578PubMed
198637232Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells.Leukemia1996https://conductscience.org/library/papers/8637232PubMed
2012010785A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.Blood2002https://conductscience.org/library/papers/12010785PubMed

See all 49 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
41772642Advances in ligand-targeted nanodelivery systems for leukemia therapy: from single- to dual-ligand strategies.J Transl Med2026https://conductscience.org/library/papers/41772642PubMed
41654885Overcoming therapeutic challenges in acute myeloid leukemia: active targeting strategies by nano-drug delivery systems.J Transl Med2026https://conductscience.org/library/papers/41654885PubMed
40427525CD99: A Key Regulator in Immune Response and Tumor Microenvironment.Biomolecules2025https://conductscience.org/library/papers/40427525PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39007347

GET https://conductscience.org/api/papers/v1/39007347/references?page=2